Lowering the Boom on High Drug Prices: HHS Plans Not a Boon to Some Players.

Abstract

The Trump administration's multipronged effort to use regulatory tools to lower drug prices includes old and new initiatives. But opposition from some players is evident in each instance. Some of that opposition may be based on sound reasoning, some of it may be based on self-interest. The author discusses advertising, protected-class drugs, what's next for rebates, and more.